德国勃林格殷格翰的思力华是什么药？

(Repimat) is the first long-acting quaternary ammonium anticholinergic bronchodilator for the treatment of chronic obstructive airway disease. In Europe, tiotropium bromide is approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Compared with Seretide and Symbicort, Siliva (tiotropium bromide dry powder inhalation) is a new, long-acting anticholinergic drug. Its application scope in China needs to be further expanded, because the price of Siliva is slightly higher, which will bring financial burden to patients. However, the drug has now been included in the scope of medical insurance, which can reduce certain financial burdens for patients.

When it comes to the use of drugs, Slihua has demonstrated convenience and specific efficacy: its convenience is mainly reflected in the inhalation method of the drug, that is, gently inhaling tiotropium bromide, a pharmaceutical ingredient, without the need to use other drugs in combination; the drug has long-acting characteristics, and shorter-acting ipratropium bromide has better medication compliance and stable and long-lasting efficacy. In terms of clinical effects, tiotropium bromide is more stable and longer-lasting than salmeterol (Seretide) and formoterol (Symbicort). Both Seretide and Symbicort need to be taken once in the morning and once in the evening, while Spirax only needs to be taken once a day.

Boehringer Ingelheim officially entered the Chinese market in 1994, with a total investment in China of more than 200 million euros. It has successively established a number of companies. While highlighting the stable and long-term efficacy of Siberia compared to competing products, it also highlights the function of tiotropium bromide, the ingredient contained in Siberia.

Because the effect of tiotropium bromide lasts longer than 24 hours, and the dissociation process from the receptor after acting on the receptor is relatively slow, Slivar can achieve the goal of only needing to take the drug once a day. This is the advantage of the product in terms of efficacy. In other aspects, there is some clinical evidence that tiotropium bromide is also better than Seretide and Symbicort in controlling symptoms and improving lung function. It can be seen that Boehringer Ingelheim has done enough work in product research and development, taking into account the needs of consumers and doing its best to meet them.

Recommended hot articles: /newsDetail/92303.html